Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Abroad (travel likely)RecruitingPHASE3

Conditions

Pancreatic Cancer · PDAC · PDAC - Pancreatic Ductal Adenocarcinoma · Resectable Pancreatic Ductal Adenocarcinoma (PDAC) · Resected Pancreatic Adenocarcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Cedars-Sinai Cancer at Cedars-Sinai Medical Center, Los Angeles, California, United States
Contact: Study coordinator (Naomi Geier) · naomi.geier@cshs.org · 310-423-4693
University of California, Los Angeles, Los Angeles, California, United States
Contact: Study coordinator (Madeleine Manahan) · mmanahan@mednet.ucla.edu · 310-633-8400
Stanford Cancer Institute, Palo Alto, California, United States
Contact: Study coordinator (Cassandra Blake) · cblake1@stanford.edu · 650-725-9895
University of California, San Francisco, San Francisco, California, United States
Contact: Study coordinator (Kevin Lopez) · Kevin.lopez@ucsf.edu · 415-502-3310
Rocky Mountain Cancer Centers, LLP, Lakewood, Colorado, United States
Hartford Healthcare, Hartford, Connecticut, United States
Contact: Study coordinator (Jonathan Steinmetz) · jonathan.steinmetz@hhchealth.org · 860-972-4183
Mayo Clinic, Jacksonville, Florida, United States
Contact: Study coordinator (Hani Babiker) · babiker.hani@mayo.edu · 520-626-7866
University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Contact: Study coordinator (Yolanda Justal) · yxj512@med.miami.edu · 305-243-2647
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
Contact: Study coordinator (Kathleen Coleman) · kathleen.marie.coleman@emory.edu · 404-251-1278
Community Health Network, Indianapolis, Indiana, United States
Contact: Study coordinator (Adam Norris) · anorris@ecommunity.com · 317-621-3858
University of Kansas Medical Center Research Institute, Inc., Lawrence, Kansas, United States
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins & Sibley Memorial Hospital, Baltimore, Maryland, United States
Contact: Study coordinator (GI Clinical Trial Referrals) · giclinicaltrials@jhmi.edu · 410-614-3644
Contact: Study coordinator (Mike Pishvaian) · 202-660-6500
Massachusetts General Hospital, Boston, Massachusetts, United States
Dana Farber Cancer Institute (DFCI), Boston, Massachusetts, United States
Study coordinator · 617-632-3000
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
Contact: Study coordinator (Ryan Carr) · carr.ryan@mayo.edu · 507-284-2511
Saint Luke's Cancer Institute, Kansas City, Missouri, United States
Contact: Study coordinator (Marc Roth) · mroth@saint-lukes.org · 816-932-2677
University of Nebraska Medical Center, Omaha, Nebraska, United States
Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
Contact: Study coordinator (Ann Lovelace) · ann.lovelace@usoncology.com · 702-609-9460
Laura and Issac Perlmutter Cancer Center at NYU Langone-Ambulatory Care Center, New York, New York, United States
Contact: Study coordinator (Mark Bond) · Ct.gov@nyulangone.org · 212-731-6120
Contact: Study coordinator (Jennifer Coffey) · Ct.gov@nyulangone.org · 212-731-6120
Columbia University Medical Center, New York, New York, United States
Study coordinator · cancerclinicaltrials@cumc.columbia.edu
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Contact: Study coordinator (Eileen O'Reilly) · oreillye@MSKCC.ORG · 646-888-4182
Duke Cancer Center, Durham, North Carolina, United States
Taylor Cancer Research Center, Maumee, Ohio, United States
Contact: Study coordinator (Stephanie Ambrose) · sambrose@tcrcpt.org · 567-402-4502
Avera Cancer Institute, Sioux Falls, South Dakota, United States
Contact: Study coordinator (Heidi McKean) · heidi.mckean@avera.org · 605-322-6900
SCRI Oncology Partners, Nashville, Tennessee, United States
Texas Oncology - DFW, Dallas, Texas, United States
Texas Oncology - Northeast Texas, Longview, Texas, United States
Contact: Study coordinator (Angie Smith) · Angie.smith2@usoncology.com
University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States
Contact: Study coordinator (Susan Sherry) · susan.sharry@hci.utah.edu · 801-585-3453
Virginia Cancer Specialists, Fairfax, Virginia, United States
CRLCC Eugene Marquis, Rennes, Cedex, France
Hôpital Paul Brousse, Villejuif, Val-De- Marne, France
IEO - Instituto Europeo di Oncologia, Milan, Italy
Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
Contact: Study coordinator (Makoto Ueno) · kccmakoto23u@gmail.com
Cancer Institute Hospital of JFCR, Tokyo, Japan
Contact: Study coordinator (Masato Ozaka) · masato.ozaka@jfcr.or.jp
Pan American Oncology Trials, LLC, San Juan, Puerto Rico
Contact: Study coordinator (Principal Investigator) · info@panoncologytrials.com · 787-407-3333
Hospital Clinic de Barcelona, Barcelona, Spain
Hospital Universitario 12 de Octubre, Madrid, Spain
Hospital Universitario Virgen del Rocio, Seville, Spain
University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Medical Centre, Birmingham, United Kingdom
Contact: Study coordinator (Shivan Shivakumar) · Shivan.Sivakumar@uhb.nhs.uk · 0121 371 3571
Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
The Royal Marsden NHS Foundation Trust, Royal Marsden Hospital-London, London, United Kingdom
Contact: Study coordinator (Naureen Starling) · gitrials@rmh.nhs.uk · 02078118460
Imperial College Healthcare NHS Foundation Trust, Hammersmith Hospital, London, United Kingdom
Contact: Study coordinator (Michela Cicchetti) · michela.cicchetti@nhs.ne · 0203 313 8364
The Christie NHS Foundation Trust, Manchester, United Kingdom

View source on ClinicalTrials.gov